BioLine RX Ltd
BLRX2.980USD
+0.060+2.05%
收盤 02/06, 16:00（美東）報價延遲15分鐘
12.97M總市值
虧損本益比TTM
關於 BioLine RX Ltd 公司
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
BioLine RX Ltd簡介
公司代碼BLRX
公司名稱BioLine RX Ltd
上市日期Jan 30, 2007
CEOSerlin (Philip Adam)
員工數量28
證券類型Depository Receipt
年結日Jan 30
公司地址Modi'in Technology Park
城市MODIIN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編7177871
電話97286429100
網址https://www.biolinerx.com/
公司代碼BLRX
上市日期Jan 30, 2007
CEOSerlin (Philip Adam)
BioLine RX Ltd公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Raphael (Rafi) Hofstein, Ph.D.
Dr. Raphael (Rafi) Hofstein, Ph.D.
Director
Director
--
--
Ms. Nurit Benjamini
Ms. Nurit Benjamini
External Director
External Director
--
--
Dr. Avraham (Avi) Molcho
Dr. Avraham (Avi) Molcho
External Director
External Director
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Sandra Panem, Ph.D.
Dr. Sandra Panem, Ph.D.
Director
Director
--
--
Ms. Mali Zeevi
Ms. Mali Zeevi
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Hillit Mannor Shachar
Dr. Hillit Mannor Shachar
Vice President - Business Development
Vice President - Business Development
--
--
Dr. Ella Sorani
Dr. Ella Sorani
Vice President - Development
Vice President - Development
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Raphael (Rafi) Hofstein, Ph.D.
Dr. Raphael (Rafi) Hofstein, Ph.D.
Director
Director
--
--
Ms. Nurit Benjamini
Ms. Nurit Benjamini
External Director
External Director
--
--
Dr. Avraham (Avi) Molcho
Dr. Avraham (Avi) Molcho
External Director
External Director
--
--
Dr. Michael J. Anghel
Dr. Michael J. Anghel
Director
Director
--
--
Mr. Philip Adam (Phil) Serlin
Mr. Philip Adam (Phil) Serlin
Chief Executive Officer
Chief Executive Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 4 小時前
更新時間: 4 小時前
持股股東
股東類型
持股股東
持股股東
佔比
Hong Seng Technology Ltd
3.92%
Citadel Advisors LLC
0.23%
Morgan Stanley & Co. LLC
0.12%
Intracoastal Capital, L.L.C.
0.07%
Rhumbline Advisers Ltd. Partnership
0.07%
其他
95.59%
持股股東
持股股東
佔比
Hong Seng Technology Ltd
3.92%
Citadel Advisors LLC
0.23%
Morgan Stanley & Co. LLC
0.12%
Intracoastal Capital, L.L.C.
0.07%
Rhumbline Advisers Ltd. Partnership
0.07%
其他
95.59%
股東類型
持股股東
佔比
Corporation
4.00%
Hedge Fund
0.23%
Research Firm
0.16%
Investment Advisor
0.14%
其他
95.47%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
62
27.70K
3.92%
--
2025Q3
65
27.70K
4.05%
-38.51K
2025Q2
64
66.21K
2.82%
+56.76K
2025Q1
62
9.46K
4.78%
-168.28K
2024Q4
61
51.31K
6.91%
-11.13K
2024Q3
60
62.45K
12.93%
-43.93K
2024Q2
64
107.06K
9.39%
+72.30K
2024Q1
62
34.99K
9.95%
-145.17K
2023Q4
66
30.65K
11.57%
-4.56K
2023Q3
69
34.99K
12.67%
+3.06K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Hong Seng Technology Ltd
170.73K
3.92%
--
--
Mar 16, 2025
Citadel Advisors LLC
10.02K
0.23%
-4.93K
-32.99%
Sep 30, 2025
Morgan Stanley & Co. LLC
5.04K
0.12%
+4.40K
+684.29%
Sep 30, 2025
Intracoastal Capital, L.L.C.
3.13K
0.07%
+3.13K
--
Mar 16, 2025
Rhumbline Advisers Ltd. Partnership
3.07K
0.07%
-1.21K
-28.19%
Sep 30, 2025
UBS Financial Services, Inc.
6.39K
0.15%
+6.39K
--
Sep 30, 2025
Wells Fargo Advisors
1.75K
0.04%
--
--
Sep 30, 2025
Morgan Stanley Smith Barney LLC
910.00
0.02%
+10.00
+1.11%
Sep 30, 2025
Nemes Rush Group, LLC.
250.00
0.01%
--
--
Sep 30, 2025
GWM Advisors LLC
107.00
0%
--
--
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
公告日期
除權除息日
類型
比率
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
Jan 17, 2025
Merger
40→1
